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ciation for Thoracic Surgerydoi:10.1016/j.jtcvs.2004.10.019Objective: Treatment options for patients with non–small cell lung cancer who are
not surgical candidates or who refuse operation are limited. Radiofrequency ablation
represents a potential less invasive option for these patients. Our initial experience
with radiofrequency ablation for peripheral, primary non–small cell lung cancer is
reported.
Methods: We treated 21 tumors in 18 patients. Median age was 75 (range 58-86)
years. Cancer stages were I (n  9), II (n  2), III (n  3), and IV (n  4). Patients
with stage IV disease included 3 with recurrence after previous lobectomies and 1
with a synchronous liver metastasis also treated with radiofrequency ablation.
Median tumor diameter was 2.8 cm (range 1.2-4.5 cm). Radiofrequency ablation
was delivered by minithoracotomy in 2 cases and by a computed tomography–
guided percutaneous approach in 16 patients. Computed tomographic and positron
emission tomographic scans were used to evaluate recurrence and radiographic
response in ablated nodules.
Results: One postoperative death occurred from pneumonia after open radiofre-
quency ablation. Median hospital stay was 2.5 days. A chest tube or pigtail catheter
was required in 7 patients (38.9%) for procedure-related pneumothoraces. At a
median follow-up of 14 months, 15 patients (83.3%) were alive. Local progression
occurred in 8 nodules (38.1%). Mean and median progression-free intervals were
16.8 and 18 months, respectively. For stage I cancers, mean progression-free
interval was 17.6 months. Median progression-free interval was not reached.
Conclusion: This study demonstrates the feasibility of radiofrequency ablation for
small, peripheral non–small cell lung cancer tumors. Local control is comparable to,
if not better than, that provided by radiotherapy. Radiofrequency ablation should
continue to be evaluated by thoracic surgeons as a noninvasive therapy for the
high-risk patient with non–small cell lung cancer.
Radiofrequency ablation (RFA) is a relatively new modality that hasbeen successfully used for the treatment of hepatic tumors.1 Duringthe past few years, an increasing number of reports have describedthe use of RFA for malignant lung nodules.2,3 Most of these havebeen case reports or small series describing primary efficacy andsafety with minimal or no follow-up. We have previously described
our early experience with RFA.4 In that initial series, most tumors were pulmonary
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TSmetastases, with only a few cases of primary non–small cell
lung cancer (NSCLC). The principal findings of our earlier
report were that RFA was more effective for smaller (5
cm) tumors, with better early survival and response to
treatment. Additionally, in our previous report we described
a modification of the Response Evaluation Criteria in Solid
Tumors (RECIST) criteria (Table 1) that was used to assess
treatment response and progression at the ablated sites.5,6
This article reports our ongoing experience with RFA for
primary NSCLC and is part of an ongoing institutional
review board–approved study that continues to accrue at the
University of Pittsburgh. The aims of this study were to
evaluate the efficacy of RFA in NSCLC and to determine
progression-free survival at intermediate follow-up.
Methods
Patient Selection
A total of 18 patients with 21 NSCLC tumors underwent RFA.
Patients included 10 men and 8 women. The median age was 75
years (range 58-86 years). Five of these patients were previously
reported on in our initial pilot study,4 and 11 are part of an ongoing
study. Inclusion criteria for this study included (1) target tumor 4
cm or smaller, (2) either evaluation by a thoracic surgeon that
patient was at high risk for operation or patient refusal of opera-
tion, (3) stage I or II NSCLC, (4) recurrent NSCLC (same histo-
logic type) after previous resection, and (5) persistent peripheral
cancer after definitive chemotherapy or radiation therapy. Exclu-
sion criteria included (1) central tumors defined as 3 cm or less
from the hilum, (2) more than three tumors, and (3) malignant




Air leak 4 d 1 5.6
Pulmonary embolus 1 5.6
*Both pneumonias occurred after open RFA procedures.
TABLE 1. Modified RECIST criteria used to evaluate treatm
Response CT mass size (RECIST)












Progression (any 2) Increase of 20% in LD of
target lesion
Soli
Target lesions represent tumors treated with RFA. SUV, Standard uptake va
FDG, fluorodeoxyglucose F18.pleural effusion. Stages of disease included I (n  9), II (n  2),
640 The Journal of Thoracic and Cardiovascular Surgery ● MarIII (n  3), and IV (n  4). The patients with stage IV disease
included 3 with recurrent cancer after a previous lobectomy (tumor
histologic type was the same as the original primary in all cases)
and 1 patient with a synchronous liver metastasis that was also
treated with RFA. Biopsy specimens were obtained in all cases
either before or at the time of RFA. The exception was if there
were any synchronous nodules present. If the computed tomo-
graphic CT and positron emission tomographic (PET) scans were
consistent with a diagnosis of cancer, then only one nodule was
sampled for biopsy. Tumor histologic types included squamous (n
 10), adenocarcinoma (n  5), adenosquamous (n  1), bron-
chiolar (n  1), and large cell undifferentiated (n  1). The
reasons for performing RFA in preference to operation included
poor pulmonary function (n  8), previous lung resection for
cancer (n  4), patient refusal of resection (n  4), high cardiac
risk (n  3), and failure of definitive chemoradiation (n  1). It
should be noted that in some cases more than one factor influenced
the decision to perform RFA. The median forced expiratory vol-
ume in 1 second, forced vital capacity, and diffusing capacity of
carbon monoxide of the patients with impaired pulmonary function
were 39.5%, 53%, and 34%, respectively. Of the 4 patients who
had undergone previous resections (3 with stage IV and with a new
primary NSCLC), 2 had impaired pulmonary function precluding
any resection. The third patient had 2 metastases in the left lower
lobe after a left upper lobectomy. After failure of chemotherapy,
RFA was selected. The fourth patient had a left lower lobe recur-
rence develop after a previous left upper lobectomy and chest wall
resection. Completion pneumonectomy was required, but because
of concerns regarding the patient’s ability to tolerate this, open
RFA was performed. The 21 RFA procedures were performed
during a 24-month period. During this time, approximately 760
lung resections for malignant tumors were performed by our
group, representing about 2.7% of our current practice.
RFA Technique
All the RFA procedures were performed by thoracic surgeons
either in the operating room or in the radiation oncology CT scan
suite. The initial procedures were performed with an open ap-
proach through a minithoracotomy (n  2). Subsequently, CT-
guided percutaneous ablation was performed in all other cases (n
 16). All procedures were performed with patients under general
response
CT mass quality PET
avity formation SUV 2.5
sity of entire lesion
ecrosis or central cavitation
uid density
Decreased SUV or area of
FDG uptake
lid appearance, no central
is or cavity
Unchanged SUV or area of
FDG uptake
ss, invasion adjacent structures Higher SUV








lue ofanesthesia. In the CT percutaneous cases, a finder needle (22-
ch 2005
after
Fernando et al General Thoracic Surgery
G
TSgauge long spinal needle) was used to determine the trajectory and
placement of the active RFA probe. The LeVeen needle electrode
(Boston Scientific Corporation, Boston, Mass) was selected ac-
cording to the diameter of the target lesion and placed into the
lesion parallel to the trajectory of the finder needle. Multiple tines
were deployed to maximize the treatment area. Generally, we
strove to achieve an ablation between 0.5 and 1 cm greater in
diameter than the maximum diameter of the cancer. Therefore an
active electrode at least 0.5 cm larger than the maximum diameter
of the tumor was selected. In some cases, a coaxial needle was
used to pass the active electrode (LeVeen electrode) into the
lesion. The shorter length of the coaxial needle relative to the
active electrode facilitated passage through the scanner, particu-
larly for a very peripheral lesion. Additionally, in cases where a
pretreatment tissue diagnosis was not available, it was possible to
pass a true-cut needle through the coaxial needle sheath and obtain
a biopsy specimen.
After RFA, CT scans and PET scans (in most patients) were
performed at 4 to 6 weeks and then at 3-month intervals. The
modified RECIST criteria described previously (Table 1) were
used to assess response. Time to progression was classified as the
time from ablation to the first sign of progressive disease. At least
two surgeons reviewed the CT and PET scans in every case to
determine whether progression had occurred.
Statistical Analysis
All data was entered into an SPSS file (version 11 for Windows;
SPSS Inc, Chicago, Ill). The 2 test was used for dichotomous
variables. Kaplan-Meier with log-rank analysis was used to eval-
uate overall and progression-free survivals and to compare pa-
Figure 1. Overall survivaltients.
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A total of 21 tumors were treated in 18 patients. The median
tumor diameter was 2.8 cm (range 1.2-4.5 cm). There was 1
perioperative death, that of a patient who had undergone
open RFA of a right upper lobe lesion in conjunction with
a right lower lobe lobectomy. This patient had a pulmonary
embolus develop, and then pneumonia with subsequent
sepsis and multisystem organ failure. Morbidity occurred in
10 patients (55.6%) but was minor in most cases. Morbidity
is detailed in Table 2. The most common complication was
the need for a chest tube or pigtail catheter for pneumotho-
rax in 7 cases (38.9%). Usually the pneumothorax was
minor in nature, with the tube removed on the first day after
the RFA. For all patients, the median duration of chest tube
placement was less than 24 hours (range 0-14 days). Median
hospital stay was 2.5 days (1-35 days) . The long chest-tube
drainage of 14 days and hospital stay of 35 days occurred in
1 of the patients treated with open RFA. Median follow-up
was 14 months (3-25 months) after RFA. Two deaths oc-
curred among the 17 hospital survivors at 1 and 4 months.
One death was related to chronic rejection after previous
lung transplantation. This patient had stage I cancer; death
occurred 4 months after RFA. The second death occurred in
a patient with stage II cancer and chronic renal failure.
Death occurred 1 month after RFA and was related to the
underlying renal disease. The Kaplan-Meier survival curve
for the 18 patients is demonstrated in Figure 1. Mean
RFA for NSCLC (n  18).survival was 20.97 months; median survival was not
c and Cardiovascular Surgery ● Volume 129, Number 3 641
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gression was seen in 8 nodules (38.1%) in 6 (33% patients).
Salvage therapy in these 6 patients included chemotherapy
and radiation (n  2), repeated RFA (n  1), chemotherapy
and completion pneumonectomy (n  1), lobectomy (n 
1), and wedge resection (n  1). The mean and median
progression-free intervals were 16.8 and 18 months, respec-
tively. Comparison of the stage I tumors with the higher
stage cancers demonstrated a trend (P  .885) favoring
stage I (Figure 2). Mean progression-free interval was 17.6
months for stage I cancers. Median progression-free interval
was not reached for stage I cancers. For the more advanced
cancers, mean and median progression-free intervals were
14.98 and 18 months, respectively.
Discussion
RFA is a minimally invasive technique for treating pulmo-
nary nodules that avoids the morbidity and mortality tradi-
tionally associated with pulmonary resection.7 Lobar resec-
tion should, however, continue to be the standard therapy
for stage I NSCLC. Previous reports have demonstrated
5-year survivals as great as 80%8 and local recurrence rates
of 5% after lobectomy for stage I NSCLC.9 For the mod-
erately compromised patient, sublobar resection is an op-
tion. The main concern with sublobar resection is the in-
creased local recurrence relative to lobectomy.9 Recent
reports, however, suggest that the use of intraoperative
adjuvant brachytherapy in combination with sublobar resec-
tion may reduce the higher local recurrence rate associated
Figure 2. Progression-free intewith sublobar resection alone.10,11
642 The Journal of Thoracic and Cardiovascular Surgery ● MarFor those patients who are unable to tolerate pulmonary
resection, external beam radiation has traditionally been
used. Treatment results are inferior to those of resection. In
a previous study of 71 node-negative patients who received
at least 60 Gy to their cancers,12 3 and 5-year survivals were
19% and 12%. Disease-free survivals were 44% and 32%. A
more recent report described results after radiation therapy
in 60 patients with stage I or II cancers.13 Local progression
occurred in 53% of patients, with a median progression-free
survival of 18.5 months and an overall median survival of
20 months. RFA compares well with these results. In our
series, when looking at all cancer stages combined, median
progression-free interval was 18 months. For the stage I
patients, median progression-free interval was not reached,
and mean progression-free interval was 17.6 months.
Some of the difficulties with standard methods of radia-
tion include the problems of radiation injury to surrounding
tissues and the difficulties of delivering a precise area of
radiation to a target area because of lung movement with
respiration. Radiation pneumonitis is a significant and po-
tentially life-threatening complication of radiation, particu-
larly for an impaired patient who is unable to undergo
resection. In one series of patients treated with definitive
radiotherapy, this complication occurred in 8.3% of pa-
tients.13 RFA avoids some of these issues and additionally
allows treatment to be given in a single setting. On the other
hand, not all tumors are amenable to RFA. We previously
reported a case of fatal hemoptysis occurring 21 days after
RFA of a central tumor metastasis.4 Because of this, we do
in 21 lung nodules after RFA.not recommend CT-guided RFA of central lesions close to
ch 2005
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to percutaneous approaches because of overlying structures,
preventing an adequate window to the lesion.
Stereotactic radiosurgery is a relatively new approach
that minimizes some of the problems with standard radia-
tion therapy and allows delivery of higher doses of radiation
to the targeted tumor.14 The accuracy is achieved by ex-
tremely precise spatial localization of the tumor and deliv-
ery of multiple cross-fired beams of directed radiation to
converge upon the tumor. A recent study demonstrated a
partial response in 87% and a complete response in 27% of
37 high-risk patients with stage I NSCLC after stereotactic
radiosurgery.15 At a median follow-up of 15.2 months, there
was local recurrence in 6 patients in this study (16.2%).15
As RFA and stereotactic radiosurgery for NSCLC become
more prevalent, further studies will be required to compare
and determine the appropriate use of each modality. Be-
cause there is overlap in the types of tumors that are suitable
for these nonresectional therapies, further studies will be
needed to address issues such as long-term effectiveness,
quality of life, and cost-effectiveness.
A problem that is challenging after RFA is the assess-
ment of treatment response. Unlike an operation in which a
cancer is removed, a residual mass associated with some
degree of scarring is usual after RFA. In some cases, this
scarring may involve a larger area than the original tumor.
PET scans may continue to have positive results, making it
difficult to assess whether viable tumor or scarring is
present. We have been using a modification of the RECIST
criteria to assess tumor progression at follow-up.4 Other
centers have been using CT densitometry protocols to help
evaluate persistent or recurrent disease.16 However, densi-
tometric techniques are time-consuming and of value only
for those patients with single nodules that have been ab-
lated. Because the inflammatory changes after RFA have
often started to subside by 3 months, the 3-month scan is
often more useful as the baseline scan against which local
progression can be judged. The American College of Sur-
geons Oncology Group will be using this same approach to
assess local control after RFA in a study (Z4033) that is
currently being developed. A goal of this study will be to
establish a common approach to treatment and follow-up of
ablated nodules in a multicenter setting.
Conclusions
RFA is a minimally invasive approach that can be used to
treat NSCLC in patients who are not candidates for pulmo-
nary resection. Intermediate results are encouraging and
appear to be at least comparable to those of external beam
radiation. As expected, treatment results are superior for
stage I tumors. It is imperative that thoracic surgeons con-
tinue to evaluate ablative techniques such as RFA as these
are introduced to clinical practice.
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Discussion
Dr John D. Mitchell (Denver, Colo). We have all become accus-
tomed to new and innovative therapies coming from the thoracic
group at the University of Pittsburgh, and your work with RFA is
no exception. I am going to move right to my questions. First, you
are using a 3-dimensional device to encompass a 3-dimensional
object, the tumor, with in most of these cases a 2-dimensional
imaging tool. How do you make sure that your treatment area
completely covers or encompasses an often very spiculated lesion?
Dr Fernando. I think that is a very good question. There really
is no other way of doing this. You have to use 2-dimensional
imaging. What we do is use a probe that is slightly bigger than the
lesion that we are treating, so for instance if we are treating a 2-cm
lesion, then we would use a 3-cm diameter probe or 3.5-cm
diameter probe. With the CT scanner that we use, we do get
c and Cardiovascular Surgery ● Volume 129, Number 3 643
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typically used to seeing on an image that you get generated in your
office. I think this may be part of the reason why we do see local
progression; we don’t get quite a perfect ablation in all cases.
Dr Mitchell. Second, although the pneumothorax rate ap-
proached about 40%, most were very minor in nature, and you are
deploying a pretty good size needle and then deploying multiple
tines out into what is often very emphysematous lung. Why don’t
you have more of a problem with persistent air leak in these
patients?
Dr Fernando. First, I would bring to your attention that only
about 50% of these patients had a pneumothorax. I think this was
because some of these patients had previous surgery, so there were
probably adhesions that prevented pneumothoraces. Also some
patients had been exposed to asbestos, which may also have been
associated with adhesions. I am surprised that pneumothoraces
aren’t a big problem. I have had 2 patients with severe emphysema
who had never been operated on before in whom at the time of the
procedure I put in a pigtail. The pigtail wasn’t enough to control
the pneumothorax. I put in one chest tube, and then actually two
chest tubes, and in 1 case we actually had to make a blow hole
postoperatively because the patient swelled up like a balloon. So
we do see this problem, but not as much as you would expect. As
I mentioned, with most of these patients we put a pigtail in at the
time of the procedure and pulled it out the next day, and that was
that.
Dr Mitchell. Third, you included a number of patients with
stage IV disease in your series. Could you elaborate a little bit
more on how you see RFA being used for stage IV disease?
Dr Fernando. I think this has to be in conjunction with your
medical oncologists and radiation oncologists. Among our patients
with stage IV disease, as I mentioned, there were 3 patients who
had previously undergone lobectomy and had a new recurrence in
another lobe with the same histologic type. These patients we
decided to treat with RFA primarily. The fourth patient again was
644 The Journal of Thoracic and Cardiovascular Surgery ● Marconsidered to have a low performance status, and the oncologist
was reluctant to treat that patient with chemotherapy, so the patient
underwent RFA ablation with laparoscopy for the liver lesion and
then we performed the CT-guided ablation of the lung lesion. I
think we are going to see more of these patients around. You know
that as thoracic surgeons we don’t typically operate on patients
with stage IV disease, but as we start becoming familiar with these
techniques and these techniques become more widespread, we are
going to see more of these patients.
Dr Mitchell. Finally, it would seem that the major therapeutic
alternative to RFA in medically inoperable patients with stage I
disease is stereotactic radiotherapy, for which better and better
survival results are being reported all the time. When and why
would you advocate the use of RFA instead of stereotactic radio-
therapy in these patients?
Dr Fernando. I don’t think that the answer as which modality,
sterotactic radiosurgery or RFA, is known yet. The same type of
data that we are starting to see reported with RFA needs to be
devoloped for sterotactic radiosurgery. In fact, we are actually
working in conjunction with the thoracic group from Stanford on
a protocol for sterotactic radiosurgery to try and look at long-term
outcomes such as survival and time to progression. I think there is
going to be a point in the future at which we will have to compare
sterotactic radiosurgery with RFA. Some situations where we can’t
use RFA include very central nodules, because we worry about
burning the tumor close to the hilum, and also very small tumors
hidden behind bony structures, particularly at the apex of the lung.
It is very hard to get a small tumor in the apex because of vascular
structures as well as the first rib and clavicle hindering access.
With sterotactic radiosurgery, you don’t have to place a probe
directly into the lesion itself. Instead, fiducials are placed around
the tumor. The radiation oncology technician then uses these
fiducials to map out the area of lung to be treated with sterotactic
radiosurgery.
ch 2005
